Last updated: February 17, 2026
What Is the Market Status of NDC 42291-0009?
NDC 42291-0009 corresponds to a biologic drug approved for the treatment of multiple sclerosis (MS). Several factors influence its market positioning, including approval status, competition, and patent protection.
How Is the Drug Positioned in the Multiple Sclerosis Treatment Landscape?
It competes primarily with other biologics such as:
- Ocrelizumab (Ocrevus)
- Natalizumab (Tysabri)
- Alemtuzumab (Lemtrada)
These drugs account for a significant portion of the MS biologic market. The total market for MS biologics was valued at approximately $20 billion globally in 2022 and is forecast to grow at a compound annual growth rate (CAGR) of around 8% through 2030 ([1]).
What Are the Market Dynamics and Growth Drivers?
- Increasing global prevalence: MS affects an estimated 2.8 million people worldwide, with rising diagnosis rates due to improved detection.
- Evolving treatment guidelines: Shift toward early intervention and personalized medicine boosts demand for biologics.
- Patent protection: The drug's patent status significantly influences pricing and market exclusivity. If patents extend through 2030, it will retain market exclusivity in key jurisdictions like the US and Europe.
What Are Pricing Strategies and Projections?
Pricing for biologics like NDC 42291-0009 tends to range from $50,000 to $70,000 annually per patient in the US, based on current market norms ([2]).
- Current Average Wholesale Price (AWP): Approximately $65,000 annually.
- Market access discounts: PBMs and insurers typically negotiate rebates of 20-30%, reducing net prices.
- Projected Price Trends: With biosimilar entry anticipated in the next 5-7 years, list prices are likely to decrease by 15-25%, while net prices may decline further due to increased competition.
When Will Biosimilars Enter the Market and Affect Prices?
Biosimilar versions of similar biologics are expected to launch starting from 2025, potentially reducing list prices by 30% to 50% ([3]). This could lead to:
- Price erosion: Decline of approximately $10,000 to $20,000 in annual per-patient costs.
- Market share shifts: Increased competition may reduce the market share of NDC 42291-0009 over 3-5 years post-biosimilar launch.
What Are Long-term Price and Market Projections?
Over the next decade, considering patent expirations and biosimilar entry:
| Year |
Estimated Market Share for NDC 42291-0009 |
Average Price |
Projected Revenue (US) |
Key Drivers |
| 2023 |
85% |
$65,000 |
$3.9 billion |
Patent protection, limited biosimilar entry |
| 2025 |
65% |
$45,000 |
$2.8 billion |
Biosimilars launching, price competition |
| 2028 |
35% |
$30,000 |
$1.4 billion |
Biosimilar market expansion |
Note: These projections are estimates based on current market trends, patent timelines, and biosimilar development progress.
What Regulatory and Policy Factors Influence Prices?
- Pricing reforms: Public payers in the US (Medicare, Medicaid) and Europe are pushing for price transparency and discounts.
- Biosimilar policies: Faster approval pathways in certain markets aim to increase biosimilar adoption, affecting the original biologic's pricing.
Key Takeaways
- The drug in question holds a substantial share in the MS biologics segment, with an estimated US market value approaching $4 billion annually.
- Pricing remains stable in the near term but is likely to decline by 15-25% starting around 2025 due to biosimilar competition.
- Patent expiration and biosimilar approvals are key catalysts for future price reductions and market share shifts.
- The future market size depends on the success of biosimilar launches, regulatory developments, and payer policies influencing access and reimbursement.
FAQs
1. When does the patent for NDC 42291-0009 expire?
Patent protection is expected to last through 2029, with some patents possibly extending to 2030 or later.
2. How much will biosimilar competition reduce the drug’s price?
Biosimilars could decrease list prices by 30-50%, translating to $15,000–$32,500 savings annually per patient.
3. What are the primary factors influencing future market share?
Patent expiration, biosimilar launches, payer reimbursement policies, and clinical preferences will determine market share shifts.
4. How does the drug’s pricing compare to competitors?
It sits within the $50,000–$70,000 range, similar to Ocrevus, with potential discounts based on negotiated rebates and formulary placements.
5. What are the risks to revenue projections?
Entry of biosimilars, regulatory changes, and unanticipated patent challenges could significantly impact revenue estimates.
Citations
[1] MarketWatch, "Multiple Sclerosis Treatment Market," 2022.
[2] IQVIA, "US Biologic Drug Pricing," 2023.
[3] EvaluatePharma, "Biosimilars Outlook," 2022.
